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Background: Serum cystatin C level is a more sensitive marker of renal dysfunction than serum creatinine level. Serum cystatin 
C level was recently reported to predict the development of cardiovascular disease. This study was performed to evaluate wheth-
er the cystatin C level is associated with coronary artery disease (CAD), independent of diabetic nephropathy. 
Methods: We conducted a case-control study to assess the relationship between serum cystatin C level and coronary artery dis-
ease in diabetic patients. Among 460 diabetic patients, 38 diabetic patients had CAD. The control group consisted of 38 diabetic 
patients who were matched to cases by age, sex, and presence/absence of diabetic nephropathy. Serum cystatin C level was mea-
sured in stored samples. 
Results: Serum cystatin C level was significantly higher in patients with diabetic nephropathy, both in CAD and non-CAD pa-
tients. However, serum cystatin C level did not differ between CAD and non-CAD patients, regardless of diabetic nephropathy. 
Conclusion: Serum cystatin C level is a marker of renal dysfunction, but not coronary artery disease, in diabetic patients. 
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INTRODUCTION
The main cause of death in diabetic patients is cardiovascular 
disease. It has been reported that two out of every three dia-
betic patients die of heart failure, myocardial infarction and 
stroke [1]. Loss of kidney function is a major risk factor for 
cardiovascular disease [2,3]. Renal dysfunction due to diabetic 
nephropathy increases the risk of cardiovascular disease, which 
is the main cause of death in diabetic patients [4]. The current 
gold standard for estimation of renal function is the glomeru-
lar filtration rate (GFR), but this test is time consuming and 
expensive, thus precluding its routine use in clinical settings. 
Estimation of GFR from prediction equations based on serum 
creatinine measurements (Cockcroft-Gault or Modification of 
Diet in Renal Disease equations) is imperfect [5]. Therefore, 
researchers have tried to develop more accurate markers for 
renal function, and serum cystatin C has recently emerged as 
a target of interest. 
  Cystatin C is a cysteine protease inhibitor with a low-mo-
lecular weight (13 kD) that is produced by all nucleated cells at 
a constant rate. It is freely filtered across the glomerular mem-
brane and is almost completely reabsorbed and catabolized in 
proximal renal tubular cells [6]. Unlike serum creatinine, cys-
tatin C is not influenced by age, sex, muscle mass, exercise or 
diet. Therefore, the serum cystatin C level is a superior marker 
for the evaluation of renal function compared to other mark-
ers such as serum creatinine or creatinine clearance [7-9]. Se-
rum cystatin C level has also been reported to have a higher 
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sensitivity and accuracy than serum creatinine for detecting 
changes in GFR in diabetic patients [10,11]. 
  It has been reported that serum cystatin C level is a stronger 
predictor of mortality and cardiovascular events than serum 
creatinine or estimated GFR in elderly patients with chronic 
renal disease or coronary heart disease [12-14]. However, few 
data exist on the relationship between serum cystatin C level 
and cardiovascular disease in diabetic patients with or without 
diabetic nephropathy. The aim of the present study was to 
evaluate whether serum cystatin C level is associated with cor-
onary artery disease (CAD) independent of diabetic nephrop-
athy.
METHODS
Study design
This was a retrospective case-control study. Among 460 dia-
betic patients who visited the Diabetes Center of Asan Medical 
Center for evaluation of micro- and macrovascular complica-
tions, 38 diabetic patients with CAD were included in the 
study. The control group consisted of 38 diabetic patients who 
were matched by age, sex, and presence/absence of diabetic 
nephropathy. After obtaining written informed consent from 
each individual and the approval of our institutional review 
committee, we obtained blood samples from each patient and 
recorded patient age, sex, blood pressure, duration of diabetes,   
and other clinical information. 
Definition of coronary artery diseases 
Patients with CAD (CAD group) were defined as patients who 
have a past history of stable angina, acute coronary syndrome 
(myocardial infarction and unstable angina), coronary bypass 
surgery or percutaneous coronary intervention. Patients with-
out CAD (non-CAD group) were defined as having no past 
history of coronary artery disease or suggestive symptoms with 
a normal electrocardiogram.  
Definition of diabetic nephropathy 
Urinary albumin excretion (UAE) was measured by radioim-
munoassay from timed overnight urine collections. Individu-
als were considered normoalbuminuric if the UAE value was 
under 20 μg/min. Microalbuminuria was defined as UAE 20 to 
200 μg/min on at least two of the three measurements. Overt 
proteinuria was defined as UAE > 200 μg/min. Azotemia was 
defined as serum creatinine > 1.5 mg/dL or estimated GFR < 
60 mL/min/1.73 m
2. 
 
Analysis of serum cystatin C 
The serum cystatin C level in the stored plasma samples was 
measured by particle-enhanced immunonephelometry using 
the N Latex Cystatin C kit (Dade Behring, Marburg, Germa-
ny) and the level was expressed as mg/dL.
Statistical analysis 
Values are expressed as the means ± standard deviation. Statis-
tical analysis was performed using SPSS version 14.0 (SPSS 
Inc., Chicago, IL, USA). The paired t-test or Wilcoxon signed-
rank test and McNemar’s test were used to assess differences in 
continuous variables and categorized variables, respectively. 
The differences in serum cystatin C levels according to the 
number of stenotic vessels in 38 diabetic patients with CAD 
were analyzed by Kruskal-Wallis analysis. Conditional logistic 
regression analysis was performed to determine the risk factor 
for CAD. Differences were classified as significant at P < 0.05. 
RESULTS
Clinical characteristics of CAD and non-CAD subjects in 
diabetic patients
Clinical characteristics between 38 CAD patients and 38 non-
CAD patients are shown in Table 1. The mean age of the two 
groups was 61.7 years and most patients had type 2 diabetes 
mellitus, except for one patient who had type 1 diabetes melli-
tus. The mean duration of diabetes did not differ between the 
CAD and non-CAD groups (15.21 ± 8.09 years vs. 14.82 ± 
7.83 years, respectively, P = 0.733). The prevalence of diabetic 
retinopathy, diabetic neuropathy and hypertension did not 
differ between the two groups. Serum cystatin C level did not 
differ between the CAD and non-CAD groups (0.87 ± 0.44 
mg/L vs. 0.84 ± 0.32 mg/L, respectively, P = 0.794).
Serum cystatin C level based on diabetic nephropathy in 
CAD and non-CAD group
The two groups were divided into three subgroups each, i.e., 
normoalbuminuric, microalbuminuria, overt proteinuria and 
azotemia groups, and the serum cystatin C level was com-
pared among the groups. The serum cystatin C level increased 
with a worsening of diabetic nephropathy, but did not differ 
between the CAD and non-CAD groups (Table 2). 97
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Serum cystatin C level according to the number of stenotic 
vessels in the CAD group
When the CAD group was divided into three subgroups, i.e., 
one vessel disease, two vessel disease, and three vessel disease, 
the serum cystatin C level according to the number of stenotic 
vessels did not show significant differences (Table 3).
Risk factor for CAD 
Conditional univariate logistic regression analysis was per-
formed to determine the risk factors for CAD. Neither cystatin 
C level nor HbA1C, duration of diabetes, serum creatinine, or 
hypertension was associated with CAD (Table 4).
DISCUSSION
In this study, we did not detect a relationship between serum 
cystatin C level and CAD in diabetic patients. This result is in 
conflict with results from previous studies, which reported 
that cystatin C level is a predictor of cardiovascular disease 
and mortality. In our study, we selected diabetic patients with 
and without CAD who were matched for age, sex and presence 
of diabetic nephropathy. Serum cystatin C level was higher in 
patients with diabetic nephropathy, but no differences were 
found between CAD and non-CAD groups. Therefore serum 
cystatin C level is associated with diabetic nephropathy, but is 
not associated with CAD. 
  Cystatin C, a cationic low-molecular weight protein (13 
kD), is freely filtered across the glomerular membrane and is 
almost completely reabsorbed in proximal renal tubular cells 
[15]. Unlike serum creatinine, for which the serum concentra-
tion is strongly affected by muscle mass, cystatin C is pro-
duced by all nucleated cells at a constant rate and its serum 
level is relatively unaffected by age, sex, body composition, 
diet, and exercise [16,17]. Based on these characteristics, cys-
Table 1. Baseline characteristics of the diabetic patients in-
cluded in this study
CAD
(n = 38)
Non-CAD
(n = 38)
P value
Age, yr 61.7 ± 7.4 61.7 ± 7.4
Sex, M/F 29/9 29/9
DM type, Type 1/Type 2 1/37 0/38 1.000
DM duration, yr 15.21 ± 8.09 14.82 ± 7.83 0.733
DM nephropathy, Y/N 16/22 16/22
   Normal 22 22
   Microalbuminuria 9 7
   Overt proteinuria or 
   azotemia
7 9
DM retinopathy, Y/N 17/21 15/23 0.774
DM neuropathy, Y/N 16/22 16/22 1.000
HTN, Y/N 27/11 22/16 0.332
Serum creatinine, mg/dL  1.07 ± 0.46  1.06 ± 0.43 0.507
HbA1C, %  7.61 ± 1.46  7.69 ± 1.64 0.627
Serum cystatin C, mg/L  0.87 ± 0.44  0.84 ± 0.32 0.794
Data are presented as means ± standard deviation. 
CAD, coronary artery disease; M, male; F, female; DM, diabetes mel-
litus; HTN, hypertension.  
Table 3. Comparisons of serum cystatin C levels according to 
the number of stenotic vessels in 38 diabetic patients with 
CAD
No. of the stenotic
vessels
No. (%)
Cystatin C 
(mg/L)
P value
1 vessel disease 12 (31.6) 1.06 ± 0.72
2 vessel disease 12 (31.6) 0.78 ± 0.20 0.940
3 vessel disease 14 (36.8) 0.79 ± 0.18
Data are presented as means ± standard deviation. 
CAD, coronary artery disease.
Table 4. Factors associated with coronary artery disease based 
on conditional univariate logistic regression analysis
Variable Odds ratio 95% CI P value
Duration, yr     1.016 0.927 to 1.115 0.730
HbA1C, %           0.964 0.713 to 1.304 0.812
Serum creatinine, mg/dL          1.044 0.364 to 2.994 0.936
HTN           1.833 0.678 to 4.957 0.232
Serum cystatin C, mg/L 1.278 0.353 to 4.633 0.709
CI, confidence interval; HTN, hypertension. 
Table 2. Serum cystatin C level among subgroups of diabetic 
nephropathy
Diabetic
nephropathy
CAD
(n = 38)
Non-CAD
(n = 38)
P value
Normal  0.71 ± 0.14  0.71 ± 0.10 0.974
Microalbuminuria  0.87 ± 0.19  0.70 ± 0.11 0.138
Overt proteinuria or
azotemia
 1.59 ± 0.92  1.24 ± 0.49 0.500
Data are presented as means ± standard deviation. 
CAD, coronary artery disease. 98
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tatin C has been extensively studied as a potential alternative 
for creatinine as a serum marker of kidney function. Many 
studies have been shown that serum cystatin C level is superi-
or to serum creatinine as an estimate for GFR, and can be used 
to detect mild renal function impairment and rapid changes in 
GFR. Also, cystatin C level is superior to creatinine for the es-
timation of GFR under conditions in which there is an altered 
creatinine production [18]. It has long been recognized that 
renal dysfunction is an important risk factor of cardiovascular 
disease. Many researchers have tried to identify more accurate 
markers for renal function and serum cystatin C level has 
drawn recent attention.  
  Serum cystatin C levels in patients with chronic renal dis-
ease are associated with cardiovascular disease mortality and 
all cause mortality [19], and were shown to predict cardiovas-
cular death, myocardial infarction and stroke in a prospective 
cohort of adults aged ≥ 65 years [12]. Serum cystatin C in pa-
tients with CAD is associated with total mortality, cardiovas-
cular events and heart failure [20], and was also found to be 
associated with total mortality in a follow up study of patients 
with acute coronary syndrome [13]. Moreover, a study in el-
derly patients without chronic renal disease showed that se-
rum cystatin C was associated with the risk of total mortality, 
cardiovascular disease mortality, myocardial infarction and 
stroke [21]. In a study of an adult population without protei-
nuria and with GFR > 60 mL/min/1.73 m
2, serum cystatin C 
level was associated with increased incidence of cardiovascu-
lar disease [22]. Finally, the serum cystatin C level in patients 
with CAD who had normal or mildly reduced kidney function 
predicted cardiovascular disease mortality after adjustment 
for potential confounders, including classical risk factors and 
N-terminal pro B-type natriuretic peptide (NT-pro BNP) [14].
  The mechanism by which serum cystatin C level and car-
diovascular disease are related has not been established. How-
ever, depending on the association of serum cystatin C and 
hsCRP levels, cystatin C level was suggested to be associated 
with inflammation [12,23]. It was also proposed that cystatin 
C has a direct effect on atherosclerosis and inflammation [24]. 
Cystatin C is the most potent endogenous inhibitor of cysteine 
proteinases such as cathepsins, elastase and papain. Because 
cysteine proteinases have a prominent role in protein catabo-
lism and the cleavage of membrane and extracellular matrix 
proteins, cystatin C probably has a central regulatory function 
in the extracellular compartment. Consequently, imbalance 
between the proteases and inhibitors may affect the cardiovas-
cular system. In addition, cystatin C is probably involved in 
the regulation of inflammatory processes, where it inhibits 
polymorphonuclear cell chemotaxis, O2-release and phagocy-
tosis [25]. Because cystatin C is an inhibitor of cathepsin, its 
concentration increases as compensation for elevated elas-
tolytic activity [26]. Cytokines related with atherosclerosis 
stimulate the production of cathepsin and increase the cysta-
tin C concentration. Despite the above mentioned mechanisms, 
there is no evidence that elevation of serum cystatin C in actu-
al clinical conditions is associated with cardiovascular disease 
by inflammation. 
  Our results are in apparent contrast with those of previous 
studies. In diabetic patients, most previous studies have pri-
marily focused the relationship with impaired renal function. 
A recent study reported a statistically important relationship 
between serum cystatin C level and CAD in type 1 diabetic 
patients, but this study had some limitations [27]; surrogate 
markers of CAD were used, rather than CAD events or death. 
More importantly, this study was limited because they did not 
consider UAE. In another study, serum cystatin C level pre-
dicted the elevation of hsCRP [28]. However, as stated above, 
this result also did not show a direct association with cardio-
vascular disease and cystatin C. A recent study showing that 
serum cystatin C is associated with the risk for cardiovascular 
disease in patients with type 2 diabetes mellitus [29] was also 
limited because it assessed estimated risk instead of recording 
cardiovascular events. 
  In our study, we did not find an association between serum 
cystatin C level and CAD. Several other studies have reported 
similar results. In patients without CAD, serum cystatin C 
predicted chronic renal disease, but not CAD [30]. In a study 
of middle-aged subjects, carotid atherosclerosis was found to 
be associated with microalbuminuria, but not serum cystatin 
C level [11]. Therefore, in most studies reporting serum cysta-
tin C as a predictor of the risk for cardiovascular disease, it is 
not clear whether cardiovascular disease was a direct effect of 
elevated level of cystatin C or indirect effect of deterioration of 
renal function. 
  In conclusion, our results suggest that serum cystatin C lev-
els are useful to assess renal function, but that they are not a 
suitable marker for CAD. However, our study is limited in that 
it is a retrospective study with a small sample size. Further pro-
spective studies with larger sample sizes are needed to evaluate 
the relationship between serum cystatin C and cardiovascular 
disease. 99
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